TransCode Therapeutics Inc
Research TransCode Therapeutics Inc (RNAZ) on Bullrun: market cap USD 2.32M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRNAZ
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.32M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 17.79M
- Free cash flow-USD 4.98M
Valuation Snapshot
latest market cap is USD 2.32M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 34.66M | -USD 19.52M | n/a | -52.59 | USD 17.81M | USD 0 | USD 10.34M |
| FY2024 | USD 0 | -USD 16.75M | -USD 13.36M | n/a | -1336.63 | USD 5.81M | USD 38.29K | -USD 2.02M |
| FY2023 | n/a | -USD 18.55M | -USD 18.11M | n/a | -3419.01 | USD 2.77M | USD 450.57K | USD 1.64M |
| FY2022 | n/a | -USD 17.56M | -USD 15.86M | n/a | -1082.79 | USD 4.97M | n/a | USD 3.24M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.32M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.69M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.47M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.27M | n/a | n/a | n/a |
About TransCode Therapeutics Inc
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is TransCode Therapeutics Inc's market cap?
TransCode Therapeutics Inc's market capitalization is USD 2.32M.
What does TransCode Therapeutics Inc do?
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.